Filing Worth Mentioning: Avista Capital Partners Gp Just Disclosed New Angiodynamics Inc Position

Filing Worth Mentioning: Avista Capital Partners Gp Just Disclosed New Angiodynamics Inc Position

The New Avista Capital Partners Gp Holding in Angiodynamics Inc

Avista Capital Partners Gp filed with the SEC SC 13D/A form for Angiodynamics Inc. The form can be accessed here: 000119312516775096. As reported in Avista Capital Partners Gp’s form, the filler as of late owns 12.8% or 4,683,008 shares of the Health Care–company.

Angiodynamics Inc stake is a new one for the and it was filed because of activity on November 18, 2016. We feel this shows Avista Capital Partners Gp’s positive view for the stock.

Reasons Why Avista Capital Partners Gp Bought – Angiodynamics Inc Stock

Item 4. Purpose of Transaction

Item 4 of the Initial Schedule 13D is amended by adding the following paragraphs immediately before the last paragraph thereof:

In connection with the underwriting agreement entered into on November 14, 2016 (the “Underwriting Agreement”) among certainof the Avista Capital Funds and Barclays Capital Inc. (the “Underwriter”) and the Agency Agreement entered into on November 14, 2016 by certain of the Avista Capital Funds (the “Agency Agreement”), on November 18,2016 the Avista Capital Funds sold an aggregate of 2,500,000 shares of Common Stock at a price of $15.68 per share of Common Stock (the “November 2016 Offering”).This summary description of the Underwriting Agreement and theAgency Agreement does not purport to be complete, and is qualified in its entirety by reference to the Underwriting Agreement and the Agency Agreement, copies of which are filed as Exhibit 5 and Exhibit 6, respectively, to this Schedule13D/A.

Pursuant to the Underwriting Agreement, the Avista Capital Funds agreed with the Underwriter, subject tocustomary exceptions, not to offer, pledge, sell, or enter into any agreement to sell or otherwise dispose of or transfer, any shares of Common Stock or securities convertible into or exchangeable or exercisable for the shares of Common Stock, for aperiod of 30 days after November 14, 2016, except with the prior written consent of the Underwriter (the “Lock-Up Agreement”).This summary description of the Lock-Up Agreement does not purport to be complete, and is qualified in itsentirety by reference to the form of Lock-Up Agreement, a copy of which is filed as Exhibit 5 to this Schedule 13D/A.

Angiodynamics Inc Institutional Sentiment

Latest Security and Exchange filings show 112 investors own Angiodynamics Inc. The institutional ownership in Q3 2015 is high, at 85.53% of the outstanding shares. This is increased by 7477416 the total institutional shares. 31764891 were the shares owned by these institutional investors. In total 9 funds opened new Angiodynamics Inc stakes, 56 increased stakes. There were 11 that closed positions and 30 reduced them.

2 managers had the stock in their top Ten. Notable investors are: Broadfin Capital Llc, Rgm Capital Llc..

Stephen Dubois Camber Capital Management Llc is an institutional investor bullish on Angiodynamics Inc, owning 258183 shares as of Q3 2015 for 0.29% of its portfolio. First Light Asset Management Llc owns 277323 shares or 1.81% of its portfolio. FL Rgm Capital Llc have 5.60% of their stock portfolio for 3181056 shares. Further, Broadfin Capital Llc reported stake worth 1.77% of its US stock portfolio. The CT Lapides Asset Management Llc owns 692100 shares. Angiodynamics Inc is 1.57% of the manager’s US portfolio.

Business Profile

AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery. The Company’s Peripheral Vascular products include Fluid Management, Venous, Thrombus Management, as well as other core products. The Company’s BioFlo products incorporate Endexo Technology into the manufacturing and design of its Vascular Access products. Its Oncology/Surgery product offerings include its Microwave Ablation products, Radiofrequency Ablation (RFA) and its NanoKnife product lines.

SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.

Insitutional Activity: The institutional sentiment increased to 2.61 in Q2 2016. Its up 0.74, from 1.87 in 2016Q1. The ratio is positive, as 11 funds sold all AngioDynamics, Inc. shares owned while 20 reduced positions. 10 funds bought stakes while 48 increased positions. They now own 24.22 million shares or 1.02% less from 24.47 million shares in 2016Q1.

C M Bidwell And Associate Limited accumulated 0.03% or 7,555 shares. Panagora Asset Mngmt holds 0% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO) for 31,077 shares. White Pine Cap Ltd Liability Corporation last reported 36,975 shares in the company. Geode Cap Mngmt Ltd Llc owns 202,875 shares or 0% of their US portfolio. Blackrock Ltd holds 0% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO) for 38,393 shares. Ahl Prtnrs Llp has 17,579 shares for 0.01% of their US portfolio. Royal Natl Bank Of Canada accumulated 18,000 shares or 0% of the stock. The Louisiana-based Louisiana State Employees Retirement System has invested 0.01% in AngioDynamics, Inc. (NASDAQ:ANGO). Gabelli Funds Ltd Liability accumulated 98,000 shares or 0.01% of the stock. National Bank Of Ny Mellon accumulated 427,529 shares or 0% of the stock. Renaissance Techs Ltd Liability Corp holds 0.01% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO) for 494,400 shares. Connor Clark And Lunn Investment Management Limited reported 11,800 shares or 0% of all its holdings. The Tennessee-based State Of Tennessee Treasury Department has invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO). California Pub Employees Retirement Sys holds 0% or 102,800 shares in its portfolio. Lapides Asset Mgmt has 638,000 shares for 1.69% of their US portfolio.

Insider Transactions: Since August 5, 2016, the stock had 0 insider purchases, and 2 sales for $65.66 million net activity. $32.90M worth of AngioDynamics, Inc. (NASDAQ:ANGO) shares were sold by Burgstahler David F. Another trade for 2.24M shares valued at $32.76 million was sold by Avista Capital Partners GP – LLC.

The stock decreased 0.54% or $0.09 on November 22, hitting $16.69. About 157,400 shares traded hands. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 35.21% since April 20, 2016 and is uptrending. It has outperformed by 30.66% the S&P500.

AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The company has a market cap of $618.47 million. The Company’s devices are used in minimally invasive, image-guided procedures. It currently has negative earnings. The Firm offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

Out of 6 analysts covering AngioDynamics (NASDAQ:ANGO), 2 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 33% are positive. $14.50 is the highest target while $14.5 is the lowest. The $14.50 average target is -13.12% below today’s ($16.69) stock price. AngioDynamics has been the topic of 8 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The stock has “Neutral” rating given by Sidoti on Wednesday, September 23. The firm has “Buy” rating given on Friday, January 8 by Canaccord Genuity. Piper Jaffray reinitiated the stock with “Neutral” rating in Friday, April 8 report. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) has “Sell” rating given on Monday, August 31 by Zacks. KeyBanc Capital Markets initiated the shares of ANGO in a report on Friday, July 24 with “Overweight” rating. The stock has “Mkt Perform” rating given by Raymond James on Tuesday, November 10. The rating was initiated by Cantor Fitzgerald with “Buy” on Friday, November 4. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) earned “Hold” rating by Canaccord Genuity on Tuesday, April 5.

Another recent and important AngioDynamics, Inc. (NASDAQ:ANGO) news was published by Globenewswire.com which published an article titled: “AngioDynamics Appoints Michael C. Greiner as New Chief Financial Officer” on July 25, 2016.

According to Zacks Investment Research, “AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. AngioDynamics, Inc. designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company’s diverse product line includes angiographic products and accessories, dialysis products, vascular access products, PTA products, drainage products, thrombolytic products and venous products.”

ANGO Company Profile

AngioDynamics, Inc., incorporated on July 30, 1992, designs, makes and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures. The Firm offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment